GAITHERSBURG, Md. - Biogen Idec Inc. unveiled details of its risk-management strategy for Tysabri (natalizumab), a proposed plan that generally received support from the FDA and multiple sclerosis patients, during the first day of a two-day public hearing on the once-heralded MS drug. (BioWorld Today) Read More
